Kedudukan dalam Saham
#33320
Cambium Bio Limited, a clinical-stage regenerative medicine company, focuses on... Cambium Bio Limited, a clinical-stage regenerative medicine company, focuses on developing biologics for ophthalmology and tissue repair applications. The company provides lead product candidate is Elate Ocular for the treatment of dry eye disease. The company also develops Progenza, a stem cell platform for knee osteoarthritis and other tissue repair indications; and Sygenus, for wound healing indications. Cambium Bio Limited is headquartered in Bella Vista, Australia.
Perubahan (1 hari)
11.11%
Perubahan (1 tahun)
17.21%
Perdagangan Cambium Bio Limited (CMB)
Harga CMB dengan permodalan pasaran b
Modal pasaran bagi Cambium Bio Limited(CMB)
Modal Pasaran: $8.30M
Sehingga August 2026, Cambium Bio Limited mempunyai modal pasaran sebanyak $8.30M. Ini menjadikan Cambium Bio Limited syarikat ke-33320th paling bernilai di dunia mengikut data kami. Kapitalisasi pasaran ialah nilai keseluruhan saham syarikat tersenarai yang berada dalam edaran dan lazimnya digunakan untuk menilai nilai syarikat tersebut.
Sejarah modal pasaran Cambium Bio Limited dari 2024 hingga 2026
CMB berbanding dengan 5 teratas yang paling popular stocks
| Harga CMB |
|
Aset B |
Pasaran B |
Hasilnya |
|
|
|
|
$5.452T
|
+65,657,675.33%
|
|
|
|
|
$4.490T
|
+54,073,980.65%
|
|
|
|
|
$4.162T
|
+50,128,479.46%
|
|
|
|
|
$3.676T
|
+44,274,720.61%
|
|
|
|
|
$2.833T
|
+34,118,716.76%
|
